December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Contact dermatitis from topicalstops list of adverse drug reactions
May 1st 2004Boca Raton, Fla. - Contact dermatitis from topical medications is the most common type of adverse drug reaction, and allergic contact dermatitis is the most common and most important form of contact dermatitis induced by topical drugs, according to James S. Taylor, M.D., head of the industrial dermatology section of the department of dermatology at the Cleveland Clinic Foundation in Cleveland. "Patients with medicament contact dermatitis usually have a good prognosis, but with a propensity for relapse," he said.
Pimecrolimus cream shows better tolerability
May 1st 2004Washington - Pimecrolimus cream 1 percent showed better local tolerability than tacrolimus ointment 0.03 percent in pediatric patients with moderate atopic dermatitis, and the patients or their primary caregivers rated most of the formulation attributes of the pimecrolimus cream as being significantly better than those of the tacrolimus ointment, according to a recent Phase IV study presented at the American Academy of Dermatology annual meeting.
Clobetasol foam effective; may be preferred to creams, ointments
May 1st 2004Washington - Clobetasol delivered in a foam vehicle is associated with significant improvement of hand dermatitis and appears to be preferred by patients over other vehicles, leading to a high rate of compliance, said J. Mark Jackson, M.D., assistant clinical professor of medicine and dermatology, division of dermatology, University of Louisville.
Pediatric MRSA skin abscessesmight not require antibiotics to heal
May 1st 2004Dallas - Most community-acquired methicillin-resistant staphylococcus aureus (MRSA) skin and soft tissue abscesses smaller than 5 cm can be managed with standard incision and drainage, without the need for antibiotic therapy, according to a new study.
'Sensitive skin' a dilemma for derms:How do you treat what you can't see?
May 1st 2004Maui, Hawaii - While complaints of "sensitive skin" may be challenging to address, dermatologists can frequently help patients obtain relief, even if there are no overt clinical manifestations to treat, according to Patricia G. Engasser, M.D.
Low-strength tacrolimus eases atopic dermatitis
May 1st 2004Washington - Results from two multicenter, randomized, double-blind trials demonstrate that tacrolimus ointment 0.03 percent (Protopic) is a safe and effective treatment for mild to moderate atopic dermatitis in pediatric patients and adults.
FDA accepts Connetics Corp. NDA filing for Extina
April 8th 2004Source: www.PRNewswire.com Connetics Corp., a specialty pharmaceutical company focused on dermatology announced Thursday, April 8 that it has received confirmation that the FDA has accepted for filing the company's NDA for Extina, as of Jan. 26, 2004, with a user fee goal date of Sept. 24, 2004.
Early eczema control linked to allergies, asthma
April 1st 2004Waikoloa, Hawaii - If eczema can be kept under better control during infancy and early childhood, it might be possible to reduce the atopic march and lessen the development of asthma and allergies in some children, said Adelaide A. Hebert, M.D. Topical immune modulators could play a role in keeping the skin barrier more intact and reducing a child's propensity to develop a high level of atopic diseases, added Dr. Hebert, professor and vice chairman, department of dermatology, University of Texas Health Science Center, Houston.